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Hypertension is a common disease that includes oxidative stress as a major feature, and oxidative stress
impairs physiological nitric oxide (NO) activity promoting cardiovascular pathophysiological mechan-
isms. While inorganic nitrite and nitrate are now recognized as relevant sources of NO after their
bioactivation by enzymatic and non-enzymatic pathways, thus lowering blood pressure, mounting evi-
dence suggests that sodium nitrite also exerts antioxidant effects. Here we show for the ﬁrst time that
sodium nitrite exerts consistent systemic and vascular antioxidant and antihypertensive effects in the
deoxycorticosterone-salt (DOCA-salt) hypertension model. This is particularly important because in-
creased oxidative stress plays a major role in the DOCA-salt hypertension model, which is less dependent
on activation of the renin-angiotensin system than other hypertension models. Indeed, antihypertensive
effects of oral nitrite were associated with increased plasma nitrite and nitrate concentrations, and
completely blunted hypertension-induced increases in plasma 8-isoprostane and lipid peroxide levels, in
vascular reactive oxygen species, in vascular NADPH oxidase activity, and in vascular xanthine oxidor-
eductase activity. Together, these ﬁndings provide evidence that the oral administration of sodium nitrite
consistently decreases the blood pressure in association with major antioxidant effects in experimental
hypertension.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Nitrate and nitrite (NO /NO3 2
− −) are not considered as simple
products of nitric oxide (NO) metabolism anymore because they
recycle back to NO under certain conditions via a new biological
nitrate–nitrite-NO pathway [1]. This pathway complements the
classic enzymatic NO formation from L-arginine by NO synthase
(NOS), especially when NOS-derived NO formation is impaired
such as during hypoxia [1]. In addition, nitrate can be bioactivated
after orally-ingested nitrate enters the enterosalivary circuit to
generate inorganic nitrite in the mouth [2,3]. Oral nitrite is then
swallowed and reduced to NO under the acidic conditions of the
stomach [3,4], which are critical to the antihypertensive effects of
oral nitrite [5,6]. However, mounting evidence now suggests that a
variety of other enzymes with nitrite reductase activity can also
systemically generate NO from nitrite [7–13] and contribute to the
its antihypertensive effects. On the other hand, nitrite signaling
may activate other relevant pathways [14] resulting inB.V. This is an open access article u
e.antihypertensive effects, such as pathways that result in anti-
oxidant effects and explain at least part of the antihypertensive
effects of this anion [15,16].
A major feature of hypertensive disorders includes oxidative
stress [17], which impairs NO bioavailability and is associated with
lower nitrite levels as compared to normotensive controls [18–20].
While antihypertensive effects of sodium nitrite have been de-
monstrated in some animal models of hypertension [11,15,16,19–
24], no previous study has addressed the possible antihypertensive
effects of oral sodium nitrite in the deoxycorticosterone-salt
(DOCA-salt) hypertension model. This is particularly important
because increased oxidative stress plays a major role in this model
of hypertension [25–27], and it also provides important informa-
tion regarding the dependence of the antihypertensive effects on
interference with the renin-angiotensin system (RAS). This is be-
cause, in contrast with the two-kidney, one-clip model [28,29], the
DOCA-salt model resembles the clinical condition of abnormal
aldosterone secretion, and therefore is less dependent on activa-
tion of the RAS, which is apparently not affected by therapy with
oral nitrite, as recently reported [21].
Given the major role of oxidative stress in the DOCA-salt hy-
pertension model [25,27,30] and the possible antioxidant effects of
sodium nitrite [15,16,31], this study aimed at examiningnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hypertension model. Consistent with previous ﬁndings, our results
show that oral sodium nitrite exerts antioxidant effects that result
lower blood pressure in this hypertension model.Materials and methods
Animals and treatments
This study followed the guidelines of the Faculty of Medicine of
Ribeirao Preto of the University of Sao Paulo, and the rats were
handled according to the guiding principles published by the Na-
tional Institutes of Health Guide for the Care and Use of Laboratory
Animals.
Male Wistar rats (180–200 g) obtained from the colony at
University of Sao Paulo (Ribeirao Preto Campus) were maintained
at room temperature (22–25 °C) on a 12-h light/dark cycle with
free access to standard rat chow and water. DOCA-salt hyperten-
sion [25,27,30] was induced after the rats underwent unine-
phrectomy under tribromoethanol (250 mg/kg i.p.) anesthesia.
One week after surgery, the rats received subcutaneous injections
of deoxycorticosterone (DOCA; 30 mg/kg/week), and their drink-
ing water was supplemented with 1.0% NaCl and 0.2% KCl. Control
rats received vehicle injections and normal tap drinking water.
The rats were randomly divided into 4 experimental groups
(n¼10/group): Unxþvehicle (uninephrectomized animals who
received tap water and daily gavage of vehicle), Unxþnitrite
(uninephrectomized animals who received tap water and daily
gavage of nitrite), DOCAþvehicle (uninephrectomized animals
who received subcutaneous injection of DOCA weekly and daily
gavage of vehicle), and DOCAþnitrite (uninephrectomized ani-
mals who received subcutaneous injection of DOCA weekly and
daily gavage of nitrite).
After 2 weeks of treatment of uninephrectomized rats with tap
water (control groups) or DOCA (hypertensive groups), the ani-
mals received a daily gavage of vehicle or sodium nitrite (15 mg/
kg) for four additional weeks. This dose of sodium nitrite was
chosen with basis on previous studies showing that it exerts re-
levant antihypertensive effects [21]. Body weight and tail systolic
blood pressure (SBP) were assessed weekly by tail-cuff plethys-
mography. To minimize the effects of stress induced by this
method on blood pressure measurement, the animals were trained
for a week before the protocol started.
Measurement of plasma nitrite concentrations
Six hours after the last nitrite gavage, the rats were anesthetized
with tribromoethanol (250 mg/kg), and arterial blood samples were
collected into tubes containing heparin and immediately cen-
trifuged at 1000g for 3 min. Plasma aliquots were stored at 70 °C
until analyzed. Plasma aliquots were analyzed in duplicate for their
nitrite content using an ozone-based reductive chemiluminescence
assay as previously described [32]. Brieﬂy, to assess nitrite content
in plasma, 200 ml of plasma samples were injected into a solution of
acidiﬁed tri-iodide, purged with nitrogen in-line with a gas-phase
chemiluminescence NO analyzer (Sievers Model 280 NO analyzer,
Boulder, CO, USA). Approximately 8 ml of tri-iodide solution (2 g
potassium iodide and 1.3 g iodine dissolved in 40 ml water with
140 ml acetic acid) was placed in the purge vessel into which
plasma samples were injected. The tri-iodide solution reduces ni-
trites to NO gas, which is detected by the NO analyzer. The data
were analyzed using the software Origin Lab 8.5.Measurement of plasma NOx (nitrateþnitrite) concentrations
The plasma NOx concentrations were determined in duplicate
by using the Griess reaction as previously described [33]. Brieﬂy,
40 ml of plasma were incubated with the same volume of nitrate
reductase buffer (0.1 M potassium phosphate, pH 7.5, containing
1 mM beta nicotinamide adenine dinucleotide phosphate, and
2 units of nitrate reductase/ml) in individual wells of 96-well plate.
Samples were allowed to incubate overnight at 37 °C in the dark.
Eighty microliters of freshly prepared Griess reagent (1% sulfani-
lamide, 0.1% naphthylethylenediamine dihydrochloride in 5%
phosphoric acid) were added to each well and the plate was in-
cubated for an additional 15 min at room temperature. A standard
nitrate curve was obtained by incubating sodium nitrate (0.2–
200 mM) with the same reductase buffer. The absorbance was
measured at 540 nm, using a microplate reader.
Assessment of plasma 8-isoprostane and lipid peroxide levels
Plasma samples from all groups were used to measure 8-iso-
prostanes (8-isoPGF2α) concentrations. The measurements were
carried out as previously described [34], with commercially
available enzyme-linked immunosorbent assay kits (Cayman
Chemical Co., Ann Arbor, MI, USA).
The plasma levels of lipid peroxide were determined by mea-
suring thiobarbituric acid reactive substances (TBARS) using a
ﬂuorimetric method (with excitation at 515 nm and emission at
553 nm) as detailed previously [35]. The lipoperoxide levels were
expressed in terms of malondialdehyde (MDA) (nmol/ml).
Measurement of vascular reactive oxygen species (ROS) production
To assess vascular oxidative stress, ROS production in the aorta
from animals was measured by dihydroethidium (DHE), a ROS-
sensitive ﬂuorescent dye, as previously described [36]. Aortic
cryosections (5 mm thick) were incubated at room temperature
with DHE (10 mmol/l) for 30 min. Sections were examined by
ﬂuorescence microscopy (Leica Imaging Systems Ltd., Cambridge,
UK) and the image was captured at X400. Red ﬂuorescence from
20 ﬁelds around the vessels was evaluated using ImageJ software
(http://rsbweb.nih.gov/ij/).
Assessment of vascular xanthine oxidoreductase activity
Aortic xanthine oxidoreductase activity was measured as pre-
viously described [11], with a commercial kit (Amplex red xan-
thine/xanthine oxidase assay kit; Molecular Probes, Eugene, OR,
USA), following the manufacturer’s instructions.
Measurement of vascular NADPH-dependent ROS production
NADPH-dependent ROS production was measured in aortic
rings from rats (n¼6–8/group) as previously described [15]. Aortic
rings were transferred to luminescence vials containing 1 ml of
Hanks’ buffer, pH 7.2. After equilibration and background counts, a
non-redox-cycling concentration of lucigenin (5 mM) and
b-NADPH (12 mM) was automatically added and the luminescence
counts were measured continuously for 15 min. in a Berthold
(FB12 single-tube luminometer) at 37 °C. Background signals from
the aortic rings were subtracted from the b-NADPH-driven signals
and the results were normalized for the dry weight and reported
as lucigenin chemiluminescence/mg of dry tissue.
Drugs and solutions
All drugs and reagents were purchased from Sigma Chemical
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before use.
Statistical analysis
The results are expressed as means7S.E.M. The comparisons
between groups were assessed by two-way analysis of variance
using Bonferroni correction (GraphPad Prism 3 Software, San
Diego, CA). A probability value o0.05 was considered signiﬁcant.Results
Sodium nitrite exerts antihypertensive effect in DOCA-salt
hypertension
Hypertension was induced in this study by surgical unine-
phrectomy (Unx) followed by weekly administration of deox-
ycorticosterone (or vehicle) along with excess salt in drinking
water. Baseline systolic blood pressure (SBP) and body weight
were similar in the four experimental groups (Fig. 1A and B;
P40.05). No signiﬁcant changes of SBP were found the Vehicle
and Nitrite groups throughout the study period. However, the
DOCA-salt treatment induced a sustained increase in SBP after the
ﬁrst and second weeks of treatment (Fig. 1A). While the SBP in-
creased further with time in the DOCAþvehicle group, daily ga-
vage with sodium nitrite (15 mg/kg) signiﬁcantly attenuated the
increases in the DOCAþnitrite group after ﬁve and six weeks of
treatment (Fig. 1A; Po0.05).
While body weight doubled in Vehicle and Nitrite groups after
6 weeks of treatment (Fig. 1B; Po0.05), DOCA-treated animals
gained less than 25% of their initial weight during the same period
(Fig. 1B; Po0.05).
Sodium nitrite treatment increases plasma nitrite and NOx
concentrations
Hypertension decreased plasma nitrite and NOx concentrations
as revealed by lower plasma nitrite and NOx levels in the DOC-
Aþvehicle group compared with the Vehicle group (Fig. 2A and B;
both Po0.05). However, treatment with sodium nitrite increased
plasma nitrite and NOx concentrations signiﬁcantly, both in con-
trols and in DOCA hypertensive rats (Fig. 2A and B; both Po0.05).
Interestingly, overall plasma nitrite concentrations remained be-
low 1 mmol/l in animals treated with sodium nitrite.
Treatment with sodium nitrite decreases the concentrations of sys-
temic markers of oxidative stress and vascular oxidative stress
To assess systemic oxidative stress associated with hyperten-
sion and possible antioxidant effects of sodium nitrite, plasma
8-isoprostanes and lipid peroxide levels expressed in terms ofFig. 1. Systolic blood pressure measured by non-invasive tail-cuff method (mmHg; pane
as mean7S.E.M (n¼8–10 per group). *Po0.05 for DOCAþvehicle versus vehicle group
DOCA groups versus control groups.malondialdehyde (MDA) concentrations were measured in plasma
samples from rats. Hypertension increased both plasma 8-iso-
prostane and MDA levels signiﬁcantly, and treatment with sodium
nitrite completely blunted these alterations (both Po0.05; Fig. 3A
and B).
To further conﬁrm these alterations in this marker of systemic
oxidative stress, reactive oxygen species production in situ was
evaluated by using the sensitive probe DHE in aortic slices from
the animals. In agreement with the systemic marker, we found
that DHE oxidation was signiﬁcantly increased in the hypertensive
DOCAþvehicle group compared to the respective control group,
and the treatment with sodium nitrite attenuated DOCA-induced
oxidative stress (both Po0.05; Fig. 4A and B).
Treatment with sodium nitrite normalizes vascular NADPH oxidase-
dependent reactive oxygen species (ROS) formation in DOCA-salt
hypertensive rats
Vascular NADPH oxidase is an important pro-oxidant enzyme,
especially in hypertension, and a previous showed that treatment
with sodium nitrite inhibits vascular NADPH oxidase activity in
renovascular hypertension [15]. Therefore, NADPH oxidase-de-
pendent ROS formation in aortas from rats were measured using
lucigenin chemiluminescence [15]. In agreement with this pre-
vious study, we found increased NADPH oxidase activity in hy-
pertensive rats compared with the control group (Fig. 5A;
Po0.05), and treatment with sodium nitrite completely blunted
hypertension-induced increases in NADPH oxidase activity
(Fig. 5A; Po0.05).
Treatment with sodium nitrite normalizes vascular xanthine oxidor-
eductase (XOR) aortic activity in DOCA-salt hypertensive rats
In addition to NADPH oxidase, aortic XOR activity has been
shown to contribute to both oxidative stress and to increased
vascular relaxing responses to sodium nitrite in hypertensive an-
imals [11]. Therefore we examined whether those modiﬁcations
would also be found in the DOCA-salt model of hypertension.
Consistent with other hypertension models, we found increased
aortic XOR activity in DOCA-salt hypertensive rats compared to the
control group, and treatment with sodium nitrite normalized XOR
activity (Fig. 5B; both Po0.05).Discussion
This is the ﬁrst study to show that oral sodium nitrite ad-
ministered orally once a day exerts antihypertensive effects in the
DOCA-salt hypertension model. Our results clearly show that
minor increases in plasma nitrite concentrations were associated
with complete blunting of DOCA-salt hypertension-induced sys-
temic and vascular oxidative stress, and of pro-oxidant enzymel A) and body weight changes (g; panel B) throughout the study. (A) Data are shown
; #Po0.05 for DOCAþnitrite group versus DOCAþvehicle group. (B) *Po0.05 for
Fig. 2. Plasma nitrite and NOx levels at end of the treatments. (A) This panel shows plasma nitrite concentration (mmol/l) assessed by reductive chemiluminescence. (B) This
panel shows plasma NOx concentrations assessed by Griess reaction. Data are shown as mean7S.E.M. (n¼5–7 per group). *Po0.05 Versus vehicle group; #Po0.05 versus
respective control group.
Fig. 3. Effects of nitrite treatment on systemic markers of oxidative stress. Panel A shows plasma 8-isoprostanes concentrations (pg/ml) and panel B shows plasma lipo-
peroxide concentrations expressed in terms of malondialdehyde (MDA) (nmol/ml) in all experimental groups. Data are shown as mean7S.E.M. (n¼4–6 per group). *Po0.05
versus vehicle; #Po0.05 versus DOCAþvehicle group.
Fig. 4. Effects of nitrite treatment on in situ vascular O2 production assessed by dihydroethidium (DHE) ﬂuorescence. Panel A shows the ﬂuorescence intensity in each
experimental group. Data are shown as mean7S.E.M. (n¼5–7 per group). *Po0.05 versus vehicle; #Po0.05 versus DOCAþvehicle group. Panel B shows representative
photomicrographs (original magniﬁcation 400) of arteries incubated in the presence of DHE, which produces a red ﬂuorescence when oxidized to hydroxyethidium by
O2 .
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Fig. 5. Sodium nitrite decreases vascular NADPH and xanthine oxidase activities. (A) NADPH oxidase activity in the aortas from rats in all experimental groups was measured
by lucigenin chemiluminescence. *Po0.05 versus vehicle group; #Po0.05 versus vehicle group and DOCAþvehicle group. (B) Xanthine oxidase activity in aortas from rats in
all experimental groups. *Po0.05 versus vehicle group; #Po0.05 versus DOCAþvehicle group. Data are shown as means7S.E.M. (n¼5 per group).
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treatment with sodium nitrite results in important antioxidant
effects [15,16,31] that may contribute to lower blood pressure in
hypertension.
Although nitrite has long been viewed as a metabolic product
of NO oxidation, this notion has changed dramatically in the last
few decades, and nitrite is now accepted as a reservoir of NO that
can be released under favorable conditions [7]. With respect to the
antihypertensive effects of inorganic nitrites, studies have shown
promising effects in different animal models of hypertension
[11,15,16,19–24], and it is generally believed that inorganic nitrites
reach the circulation and then are reduced to form the potent
vasodilator NO by a variety of enzymes or other proteins with
nitrite-reductase activity including vascular [15] or erythrocytic
[22] XOR, even though a variety of other enzymatic pathways may
potentially convert nitrite into NO [1,3]. However, the mechanisms
explaining antihypertensive effects of nitrite are still poorly un-
derstood, and therefore examining the effects of nitrite in different
hypertension models may offer improved mechanistic insights
about this issue.
While Classen et al. [37] were ﬁrst to show antihypertensive
effects of nitrite, studies by other groups have conﬁrmed this
ﬁnding in different models of hypertension [11,15,20,38]. How-
ever, no previous study has shown antihypertensive effects of ni-
trite in the DOCA-salt experimental model, which is a low-renin
model, and highly dependent on sodium and increased oxidative
stress [25–27]. This is particularly important because increased
oxidative stress plays a major role in the DOCA-salt hypertension
model, which is less dependent on activation of the renin–angio-
tensin system than other hypertension models. Interestingly, so-
dium nitrite exerted major antihypertensive effects in rats with
renovascular hypertension (two-kidney, one-clip model), which is
a classical renin-dependent hypertension model [26], with in-
creased angiotensin-converting enzyme activity [39,40], even
though nitrite therapy apparently does not affect the activity of
this important enzyme [21].
The antihypertensive effects shown in the present study agree
with those reported after treatment with nitrate (instead of ni-
trite) in a salt-induced hypertension model [24], and the me-
chanism explaining the antihypertensive effects may involve an-
tioxidant effects of nitrite on renal microvasculature [16]. Indeed, a
recent study showed that nitrite counteracts angiotensin II-in-
duced vasoconstriction of renal afferent arteriole as a result of
inhibition of NADPH oxidase activity by nitrite [16]. Interestingly,
XOR was involved in this effect because it catalyzed nitritereduction to NO [16]. Supporting these previous ﬁndings, our re-
sults showed that nitrite lowered blood pressure and blunted
hypertension-induced increases in vascular NADPH-dependent
ROS formation and XOR activity. However, our ﬁndings are cer-
tainly not explained only by nitrite effects on renal micro-
vasculature. This is because angiotensin II concentrations are not
increased in the DOCA-salt model (this is a low-renin model [26]).
In fact, we found that treatment with sodium nitrite completely
blunted the increases in two relevant markers of systemic oxida-
tive stress (plasma 8-isoprostanes and MDA concentrations), thus
indicating that this treatment exerted antioxidant effects not
limited to a particular vascular bed, as previously suggested
[15,31]. Although we have not studied aortic relaxation, it is pos-
sible that nitrite treatment may have improved vascular function
in the present study.
Taken together, our results show that sodium nitrite counter-
acts the oxidative stress associated with DOCA-salt hypertension
and may therefore improve NO activity in a variety of vascular
beds, thus reducing blood pressure. In fact, the reductions in
plasma nitrite and NOx concentrations that we found in DOCA-salt
hypertensive rats compared with controls indicates that NO
bioavailability is decreased in this hypertension model, and re-
storing systemic and vascular NO bioavailability may improve
vascular dysfunction of hypertension and lower blood pressure, as
previously shown [35]. Moreover, the important reductions in
vascular oxidative stress that we found may prevent the activation
of various mechanisms involved in vascular remodeling associated
with hypertension, particularly matrix metalloproteinases (MMP)
[41]. Indeed, nitrite [42] and other antihypertensive drugs with
antioxidant effects [36,43,44] attenuated MMP activation and
vascular remodeling of hypertension.
In conclusion, our results show that sodium nitrite exerts an-
tioxidant and antihypertensive effects in the DOCA-salt model of
hypertension probably as a result of inhibited NADPH oxidase and
XOR activity. Our ﬁndings may have relevant implications, not only
in terms of lowering blood pressure but also to prevent long term
cardiovascular modiﬁcations associated with oxidative stress and
hypertension [45].Acknowledgments
This work was supported by Fundação de Aparo a Pesquisa do
Estado de São Paulo (FAPESP), Conselho Nacional de
J.H. Amaral et al. / Redox Biology 5 (2015) 340–346 345Desenvolvimento Cientíﬁco e Tecnológico (CNPq), and Co-
ordenação de Aperfeiçoamento de Pessoal de Nivel Superior
(CAPES).
The authors thank Sandra de Oliveira Conde for excellent
technical support.References
[1] M.T. Gladwin, A.N. Schechter, D.B. Kim-Shapiro, R.P. Patel, N. Hogg, S. Shiva, R.
O. Cannon 3rd, M. Kelm, D.A. Wink, M.G. Espey, E.H. Oldﬁeld, R.M. Pluta, B.
A. Freeman, J.R. Lancaster Jr., M. Feelisch, J.O. Lundberg, The emerging biology
of the nitrite anion, Nat. Chem. Biol. 1 (6) (2005) 308–314, http://dx.doi.org/
10.1038/nchembio1105-308 16408064.
[2] V. Kapil, A.J. Webb, A. Ahluwalia, Inorganic nitrate and the cardiovascular
system, Heart 96 (21) (2010) 1703–1709, http://dx.doi.org/10.1136/
hrt.2009.180372 20736204.
[3] J.O. Lundberg, M.T. Gladwin, A. Ahluwalia, N. Benjamin, N.S. Bryan, A. Butler,
P. Cabrales, A. Fago, M. Feelisch, P.C. Ford, B.A. Freeman, M. Frenneaux,
J. Friedman, M. Kelm, C.G. Kevil, D.B. Kim-Shapiro, A.V. Kozlov, J.R. Lancaster,
D.J. Lefer, K. McColl, K. McCurry, R.P. Patel, J. Petersson, T. Rassaf, V.P. Reutov, G.
B. Richter-Addo, A. Schechter, S. Shiva, K. Tsuchiya, E.E. van Faassen, A.J. Webb,
B.S. Zuckerbraun, J.L. Zweier, E. Weitzberg, Nitrate and nitrite in biology, nu-
trition and therapeutics, Nat. Chem. Biol. 5 (12) (2009) 865–869, http://dx.doi.
org/10.1038/nchembio.260 19915529.
[4] G.M. McKnight, L.M. Smith, R.S. Drummond, C.W. Duncan, M. Golden,
N. Benjamin, Chemical synthesis of nitric oxide in the stomach from dietary
nitrate in humans, Gut 40 (2) (1997) 211–214, http://dx.doi.org/10.1136/
gut.40.2.211 9071933.
[5] J.H. Amaral, M.F. Montenegro, L.C. Pinheiro, G.C. Ferreira, R.P. Barroso, A.
J. Costa-Filho, J.E. Tanus-Santos, Tempol enhances the antihypertensive effects
of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide
formation, Free Radic. Biol. Med. 65 (2013) 446–455, http://dx.doi.org/10.1016/
j.freeradbiomed.2013.07.032 23892053.
[6] L.C. Pinheiro, M.F. Montenegro, J.H. Amaral, G.C. Ferreira, A.M. Oliveira, J.
E. Tanus-Santos, Increase in gastric pH reduces hypotensive effect of oral so-
dium nitrite in rats, Free Radic. Biol. Med. 53 (4) (2012) 701–709, http://dx.doi.
org/10.1016/j.freeradbiomed.2012.06.001 22721923.
[7] K. Cosby, K.S. Partovi, J.H. Crawford, R.P. Patel, C.D. Reiter, S. Martyr, B.K. Yang,
M.A. Waclawiw, G. Zalos, X. Xu, K.T. Huang, H. Shields, D.B. Kim-Shapiro, A.
N. Schechter, R.O. Cannon, M.T. Gladwin, Nitrite reduction to nitric oxide by
deoxyhemoglobin vasodilates the human circulation, Nat. Med. 9 (12) (2003)
1498–1505, http://dx.doi.org/10.1038/nm954 14595407.
[8] S. Shiva, Z. Huang, R. Grubina, J. Sun, L.A. Ringwood, P.H. MacArthur, X. Xu,
E. Murphy, V.M. Darley-Usmar, M.T. Gladwin, Deoxymyoglobin is a nitrite
reductase that generates nitric oxide and regulates mitochondrial respiration,
Circ. Res. 100 (5) (2007) 654–661, http://dx.doi.org/10.1161/01.
RES.0000260171.52224.6b 17293481.
[9] A. Webb, R. Bond, P. McLean, R. Uppal, N. Benjamin, A. Ahluwalia, Reduction of
nitrite to nitric oxide during ischemia protects against myocardial ischemia-
reperfusion damage, Proc. Natl. Acad. Sci. U. S. A. 101 (37) (2004)
13683–13688, http://dx.doi.org/10.1073/pnas.0402927101 15347817.
[10] H. Li, H. Cui, T.K. Kundu, W. Alzawahra, J.L. Zweier, Nitric oxide production
from nitrite occurs primarily in tissues not in the blood: critical role of xan-
thine oxidase and aldehyde oxidase, J. Biol. Chem. 283 (26) (2008)
17855–17863, http://dx.doi.org/10.1074/jbc.M801785200 18424432.
[11] M.F. Montenegro, L.C. Pinheiro, J.H. Amaral, G.C. Ferreira, R.L. Portella, J.
E. Tanus-Santos, Vascular xanthine oxidoreductase contributes to the anti-
hypertensive effects of sodium nitrite in L-NAME hypertension, Naunyn
Schmiedebergs Arch. Pharmacol. 387 (6) (2014) 591–598, http://dx.doi.org/
10.1007/s00210-014-0970-8 24658348.
[12] C. Gautier, E. van Faassen, I. Mikula, P. Martasek, A. Slama-Schwok, Endothelial
nitric oxide synthase reduces nitrite anions to NO under anoxia, Biochem.
Biophys. Res. Commun. 341 (3) (2006) 816–821, http://dx.doi.org/10.1016/j.
bbrc.2006.01.031 16442076.
[13] A.V. Kozlov, K. Staniek, H. Nohl, Nitrite reductase activity is a novel function of
mammalian mitochondria, FEBS Lett. 454 (1–2) (1999) 127–130, http://dx.doi.
org/10.1016/S0014-5793(99)00788-7 10413109.
[14] N.S. Bryan, B.O. Fernandez, S.M. Bauer, M.F. Garcia-Saura, A.B. Milsom,
T. Rassaf, R.E. Maloney, A. Bharti, J. Rodriguez, M. Feelisch, Nitrite is a signaling
molecule and regulator of gene expression in mammalian tissues, Nat. Chem.
Biol. 1 (5) (2005) 290–297, http://dx.doi.org/10.1038/nchembio734 16408059.
[15] M.F. Montenegro, J.H. Amaral, L.C. Pinheiro, E.K. Sakamoto, G.C. Ferreira, R.
I. Reis, D.M. Marçal, R.P. Pereira, J.E. Tanus-Santos, Sodium nitrite down-
regulates vascular NADPH oxidase and exerts antihypertensive effects in hy-
pertension, Free Radic. Biol. Med. 51 (1) (2011) 144–152, http://dx.doi.org/
10.1016/j.freeradbiomed.2011.04.005 21530643.
[16] X. Gao, T. Yang, M. Liu, M. Peleli, C. Zollbrecht, E. Weitzberg, J.O. Lundberg, A.
E. Persson, M. Carlström, NADPH oxidase in the renal microvasculature is a
primary target for blood pressure-lowering effects by inorganic nitrate and
nitrite, Hypertension 65 (1) (2015) 161–170, http://dx.doi.org/10.1161/HY-
PERTENSIONAHA.114.04222 25312440.
[17] J. de Champlain, R. Wu, H. Girouard, M. Karas, A. EL Midaoui, M.A. Laplante,L. Wu, Oxidative stress in hypertension, Clin. Exp. Hypertens. 26 (7–8) (2004)
593–601, http://dx.doi.org/10.1081/CEH-200031904 15702613.
[18] H.F. Gomes, A.C. Palei, J.S. Machado, L.M. da Silva, M.F. Montenegro, A.
A. Jordão, G. Duarte, J.E. Tanus-Santos, R.C. Cavalli, V.C. Sandrim, Assessment of
oxidative status markers and NO bioavailability in hypertensive disorders of
pregnancy, J. Hum. Hypertens. 27 (6) (2013) 345–348, http://dx.doi.org/
10.1038/jhh.2012.58 23303400.
[19] V.C. Sandrim, M.F. Montenegro, A.C. Palei, I.F. Metzger, J.T. Sertorio, R.C. Cavalli,
J.E. Tanus-Santos, Increased circulating cell-free hemoglobin levels reduce
nitric oxide bioavailability in preeclampsia, Free Radic. Biol. Med. 49 (3) (2010)
493–500, http://dx.doi.org/10.1016/j.freeradbiomed.2010.05.012 20510352.
[20] M.F. Montenegro, L.C. Pinheiro, J.H. Amaral, D.M.O. Marçal, A.C.T. Palei, A.
J. Costa-Filho, J.E. Tanus-Santos, Antihypertensive and antioxidant effects of a
single daily dose of sodium nitrite in a model of renovascular hypertension,
Naunyn Schmiedebergs Arch. Pharmacol. 385 (5) (2012) 509–517, http://dx.
doi.org/10.1007/s00210-011-0712-0 22262021.
[21] L.C. Pinheiro, J.H. Amaral, G.C. Ferreira, M.F. Montenegro, G.H. Oliveira-Paula, J.
E. Tanus-Santos, The antihypertensive effects of sodium nitrite are not asso-
ciated with circulating angiotensin converting enzyme inhibition, Nitric Oxide
40 (2014) 52–59, http://dx.doi.org/10.1016/j.niox.2014.05.009 24878382.
[22] S.M. Ghosh, V. Kapil, I. Fuentes-Calvo, K.J. Bubb, V. Pearl, A.B. Milsom,
R. Khambata, S. Maleki-Toyserkani, M. Yousuf, N. Benjamin, A.J. Webb, M.
J. Caulﬁeld, A.J. Hobbs, A. Ahluwalia, Enhanced vasodilator activity of nitrite in
hypertension: critical role for erythrocytic xanthine oxidoreductase and
translational potential, Hypertension 61 (5) (2013) 1091–1102, http://dx.doi.
org/10.1161/HYPERTENSIONAHA.111.00933 23589565.
[23] M. Carlström, M. Liu, T. Yang, C. Zollbrecht, L. Huang, M. Peleli, S. Borniquel,
H. Kishikawa, M. Hezel, A.E. Persson, E. Weitzberg, J.O. Lundberg, Cross-talk
between nitrate–Nitrite–NO and NO synthase pathways in control of vascular
NO homeostasis, Antioxid. Redox Signal. (2014), http://dx.doi.org/10.1089/
ars.2013.5481 24224525.
[24] M. Carlström, A.E. Persson, E. Larsson, M. Hezel, P.G. Scheffer, T. Teerlink,
E. Weitzberg, J.O. Lundberg, Dietary nitrate attenuates oxidative stress, pre-
vents cardiac and renal injuries, and reduces blood pressure in salt-induced
hypertension, Cardiovasc. Res. 89 (3) (2011) 574–585, http://dx.doi.org/
10.1093/cvr/cvq366 21097806.
[25] Q.Z. Chen, W.Q. Han, J. Chen, D.L. Zhu, Y. Chen-Yan, P.J. Gao, Anti-stiffness ef-
fect of apocynin in deoxycorticosterone acetate-salt hypertensive rats via in-
hibition of oxidative stress, Hypertens. Res. 36 (4) (2013) 306–312, http://dx.
doi.org/10.1038/hr.2012.170 23160437.
[26] K.V. Sarikonda, R.E. Watson, O.C. Opara, D.J. Dipette, Experimental animal
models of hypertension, J. Am. Soc. Hypertens. 3 (3) (2009) 158–165, http:
//dx.doi.org/10.1016/j.jash.2009.02.003 20409957.
[27] A. Fujii, D. Nakano, M. Katsuragi, M. Ohkita, M. Takaoka, Y. Ohno,
Y. Matsumura, Role of gp91phox-containing NADPH oxidase in the deox-
ycorticosterone acetate-salt-induced hypertension, Eur. J. Pharmacol. 552 (1–
3) (2006) 131–134, http://dx.doi.org/10.1016/j.ejphar.2006.09.039 17064681.
[28] A. Martins-Oliveira, M.M. Castro, D.M. Oliveira, E. Rizzi, C.S. Ceron,
D. Guimaraes, R.I. Reis, C.M. Costa-Neto, D.E. Casarini, A.A. Ribeiro, R.F. Gerlach,
J.E. Tanus-Santos, Contrasting effects of aliskiren versus losartan on hy-
pertensive vascular remodeling, Int. J. Cardiol. 167 (4) (2013) 1199–1205, http:
//dx.doi.org/10.1016/j.ijcard.2012.03.137 22483258.
[29] C.S. Ceron, E. Rizzi, D.A. Guimaraes, A. Martins-Oliveira, S.B. Cau, J. Ramos, R.
F. Gerlach, J.E. Tanus-Santos, Time course involvement of matrix metallopro-
teinases in the vascular alterations of renovascular hypertension, Matrix Biol.
J. Int. Soc. Matrix Biol. 31 (4) (2012) 261–270, http://dx.doi.org/10.1016/j.
matbio.2012.01.009 22342460.
[30] M. Gómez-Guzmán, R. Jiménez, M. Sánchez, M.J. Zarzuelo, P. Galindo, A.
M. Quintela, R. López-Sepúlveda, M. Romero, J. Tamargo, F. Vargas, F. Pérez-
Vizcaíno, J. Duarte, Epicatechin lowers blood pressure, restores endothelial
function, and decreases oxidative stress and endothelin-1 and NADPH oxidase
activity in DOCA-salt hypertension, Free Radic. Biol. Med. 52 (1) (2012) 70–79,
http://dx.doi.org/10.1016/j.freeradbiomed.2011.09.015 22001745.
[31] M. Singh, A. Arya, R. Kumar, K. Bhargava, N.K. Sethy, Dietary nitrite attenuates
oxidative stress and activates antioxidant genes in rat heart during hypobaric
hypoxia, Nitric Oxide 26 (1) (2012) 61–73, http://dx.doi.org/10.1016/j.
niox.2011.12.002 22197744.
[32] C.A. Dias-Junior, M.T. Gladwin, J.E. Tanus-Santos, Low-dose intravenous nitrite
improves hemodynamics in a canine model of acute pulmonary throm-
boembolism, Free Radic. Biol. Med. 41 (12) (2006) 1764–1770, http://dx.doi.
org/10.1016/j.freeradbiomed.2006.08.022 17157179.
[33] M.F. Montenegro, L.R. Pessa, V.A. Gomes, Z. Desta, D.A. Flockhart, J.E. Tanus-
Santos, Assessment of vascular effects of tamoxifen and its metabolites on the
rat perfused hindquarter vascular bed, Basic Clin. Pharmacol. Toxicol. 104 (5)
(2009) 400–407, http://dx.doi.org/10.1111/j.1742-7843.2009.00377.x
19413660.
[34] P.S. Silva, V. Fontana, A.C. Palei, J.T. Sertório, C. Biagi, J.E. Tanus-Santos, Anti-
hypertensive effects exerted by enalapril in mild to moderate hypertension are
not associated with changes in the circulating levels of nitric oxide-related
markers, Eur. J. Clin. Pharmacol. 67 (4) (2011) 365–370, http://dx.doi.org/
10.1007/s00228-011-1003-x 21305271.
[35] D.A. Guimarães, E. Rizzi, C.S. Ceron, L.C. Pinheiro, R.F. Gerlach, J.E. Tanus-
Santos, Atorvastatin and sildenaﬁl lower blood pressure and improve en-
dothelial dysfunction, but only atorvastatin increases vascular stores of nitric
oxide in hypertension, Redox Biol. 1 (2013) 578–585, http://dx.doi.org/
10.1016/j.redox.2013.11.004 24363994.
J.H. Amaral et al. / Redox Biology 5 (2015) 340–346346[36] C.S. Ceron, E. Rizzi, D.A. Guimarães, A. Martins-Oliveira, R.F. Gerlach, J.E. Tanus-
Santos, Nebivolol attenuates prooxidant and proﬁbrotic mechanisms involving
TGF-beta and MMPs, and decreases vascular remodeling in renovascular hy-
pertension, Free Radic. Biol. Med. 65 (2013) 47–56, http://dx.doi.org/10.1016/j.
freeradbiomed.2013.06.033 23806385.
[37] H.G. Classen, C. Stein-Hammer, H. Thöni, Hypothesis: the effect of oral nitrite
on blood pressure in the spontaneously hypertensive rat. Does dietary nitrate
mitigate hypertension after conversion to nitrite? J. Am. Coll. Nutr. 9 (5) (1990)
500–502, http://dx.doi.org/10.1080/07315724.1990.10720407 2258537.
[38] K. Tsuchiya, Y. Kanematsu, M. Yoshizumi, H. Ohnishi, K. Kirima, Y. Izawa,
M. Shikishima, T. Ishida, S. Kondo, S. Kagami, Y. Takiguchi, T. Tamaki, Nitrite is
an alternative source of NO in vivo, Am. J. Physiol. Heart Circ. Physiol. 288 (5)
(2005) H2163–H2170, http://dx.doi.org/10.1152/ajpheart.00525.2004
15626692.
[39] C.S. Ceron, E. Rizzi, D.A. Guimaraes, A. Martins-Oliveira, S.B. Cau, J. Ramos, R.
F. Gerlach, J.E. Tanus-Santos, Time course involvement of matrix metallopro-
teinases in the vascular alterations of renovascular hypertension, Matrix Biol.
31 (4) (2012) 261–270, http://dx.doi.org/10.1016/j.matbio.2012.01.009
22342460.
[40] A. Martins-Oliveira, M.M. Castro, D.M. Oliveira, E. Rizzi, C.S. Ceron,
D. Guimaraes, R.I. Reis, C.M. Costa-Neto, D.E. Casarini, A.A. Ribeiro, R.F. Gerlach,
J.E. Tanus-Santos, Contrasting effects of aliskiren versus losartan on hy-
pertensive vascular remodeling, Int. J. Cardiol. 167 (4) (2013) 1199–1205, http:
//dx.doi.org/10.1016/j.ijcard.2012.03.137 22483258.
[41] M.M. Castro, E. Rizzi, G.J. Rodrigues, C.S. Ceron, L.M. Bendhack, R.F. Gerlach, J.E. Tanus-Santos, Antioxidant treatment reduces matrix metalloproteinase-2-
induced vascular changes in renovascular hypertension, Free Radic. Biol. Med.
46 (9) (2009) 1298–1307, http://dx.doi.org/10.1016/j.free-
radbiomed.2009.02.011 19248829.
[42] C.A. Dias-Junior, S.B. Cau, A.M. Oliveira, M.M. Castro, M.F. Montenegro, R.
F. Gerlach, J.E. Tanus-Santos, Nitrite or sildenaﬁl, but not BAY 41–2272, blunt
acute pulmonary embolism-induced increases in circulating matrix metallo-
proteinase-9 and oxidative stress, Thromb. Res. 124 (3) (2009) 349–355, http:
//dx.doi.org/10.1016/j.thromres.2008.12.006 19150571.
[43] C.S. Ceron, M.M. Castro, E. Rizzi, M.F. Montenegro, V. Fontana, M.C. Salgado, R.
F. Gerlach, J.E. Tanus-Santos, Spironolactone and hydrochlorothiazide exert
antioxidant effects and reduce vascular matrix metalloproteinase-2 activity
and expression in a model of renovascular hypertension, Br. J. Pharmacol. 160
(1) (2010) 77–87, http://dx.doi.org/10.1111/j.1476-5381.2010.00678.x
20331602.
[44] D.M. Marçal, E. Rizzi, A. Martins-Oliveira, C.S. Ceron, D.A. Guimaraes, R.
F. Gerlach, J.E. Tanus-Santos, Comparative study on antioxidant effects and
vascular matrix metalloproteinase-2 downregulation by dihydropyridines in
renovascular hypertension, Naunyn Schmiedebergs Arch. Pharmacol. 383 (1)
(2011) 35–44, http://dx.doi.org/10.1007/s00210-010-0573-y 21058008.
[45] M.M. Castro, J.E. Tanus-Santos, Inhibition of matrix metalloproteinases
(MMPs) as a potential strategy to ameliorate hypertension-induced cardio-
vascular alterations, Curr. Drug Targets. 14 (3) (2013) 335–343 23316965.
